Skip to main content

Pulmonary Hypertension

  • Chapter
  • First Online:
MGH Cardiology Board Review

Abstract

The right ventricular-pulmonary vascular unit is a low resistance, high compliance system that is normally capable of accommodating large increases in blood flow with a minimal increment in pressure. The development of chronically elevated pulmonary arterial pressures, either in unselected populations or in individuals with a variety of cardiopulmonary diseases, is increasingly recognized to be associated with a markedly increased risk of mortality. Regardless of the etiology, pulmonary hypertension leads to right ventricular dysfunction that is closely associated with impaired exercise capacity, renal and hepatic dysfunction. This chapter will briefly review the epidemiology and pathophysiology of pulmonary hypertension (PH) in addition to current diagnostic and treatment approaches with particular emphasis on PH arising in the setting of other cardiovascular diseases.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Subscribe and save

Springer+ Basic
EUR 32.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or eBook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Similar content being viewed by others

REFERENCES

  1. McLaughlin VV, Archer SL, Badesch DB, Barst RB, Farber HW, Lindner JR, ACCF/AHA, et al. Expert consensus document on pulmonary hypertension: a report of the American College of Cardiology Foundation task force on expert consensus documents and the American Heart Association. J Am Col Cardiol. 2009;2009(53):1573–619.

    Article  Google Scholar 

  2. Galie N, Humbert M, Vachiery JL, et al. 2015 ESC/ERS guidelines for the diagnosis and treatment of pulmonary hypertension: the joint task force for the diagnosis and treatment of pulmonary hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). Eur Respir J. 2015;46:903–75.

    Article  CAS  PubMed  Google Scholar 

  3. Chatterjee N, Lewis G. What is the prognostic significance of pulmonary hypertension in heart failure? Circ Heart Fail. 2011;4:541–5.

    Article  PubMed  PubMed Central  Google Scholar 

  4. Rich S, Kaufmann E, Levy PS. The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension. N Engl J Med. 1992;327:76–81.

    Article  CAS  PubMed  Google Scholar 

  5. Sitbon O, Humbert M, Jais X, et al. Long-term response to calcium channel blockers in idiopathic pulmonary arterial hypertension. Circulation. 2005;111:3105–11.

    Article  CAS  PubMed  Google Scholar 

  6. Humbert M, Sitbon O, Chaouat A, et al. Pulmonary arterial hypertension in France: results from a national registry. Am J Respir Crit Care Med. 2006;173:1023–30.

    Article  PubMed  Google Scholar 

  7. Benza RL, Miller DP, Bartst RJ, et al. An evaluation of long-term survival from time of diagnosis in pulmonary arterial hypertension from the REVEAL registry. Chest. 2012;142:448–56.

    Article  PubMed  Google Scholar 

  8. Johnson SR, Mehta S, Granton JT. Anticoagulation in pulmonary arterial hypertension: a qualitative systematic review. Eur Respir J. 2006;28:999–1004.

    Article  CAS  PubMed  Google Scholar 

  9. Olsson KM, Delcroix M, Ghofrani HA, et al. Anticoagulation and survival in pulmonary arterial hypertension: results from the comparative, prospective registry of newly initiated therapies for pulmonary hypertension (COMPERA). Circulation. 2014;129:57–65.

    Article  CAS  PubMed  Google Scholar 

  10. Preston IR, Roberts KE, Miller DP, et al. Effect of warfarin treatment on survival in pulmonary arterial hypertension (PAH) in the registry to evaluate early and long-term PAH disease management (REVEAL). Circulation. 2015;132:2403–11.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Barst RJ, Rubin LJ, Long WA, et al. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. The primary pulmonary hypertension study group. N Engl J Med. 1996;334:296–302.

    Article  CAS  PubMed  Google Scholar 

  12. Simonneau G, Barst RJ, Galie N, et al. Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial. Am J Respir Crit Care Med. 2002;165:800–4.

    Article  PubMed  Google Scholar 

  13. Olschewski H, Simonneau G, Galie N, et al. Inhaled iloprost for severe pulmonary hypertension. N Engl J Med. 2002;347:322–9.

    Article  CAS  PubMed  Google Scholar 

  14. Simonneau G, Torbicki A, Hoeper MM, et al. Selexipag, an oral, selective prostacyclin receptor agonist for the treatment of pulmonary arterial hypertension. Eur Respir J. 2012;40:874–80.

    Article  CAS  PubMed  Google Scholar 

  15. McLaughlin VV, Channick R, Chin KM, et al. Effect of selexipag on morbidity/mortality in pulmonary arterial hypertension: results of the GRIPHON study. J Am Coll Cardiol. 2015;65(Suppl A):A380.

    Google Scholar 

  16. Channick RN, Simonneau G, Sitbon O, et al. Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study. Lancet. 2001;358:1119–23.

    Article  CAS  PubMed  Google Scholar 

  17. Galiè N, Beghetti M, Gatzoulis MA, et al. Bosentan therapy in patients with Eisenmenger syndrome: a multicenter, double-blind, randomized, placebo-controlled study. Circulation. 2006;114:48–54.

    Article  PubMed  CAS  Google Scholar 

  18. Galie N, Rubin L, Hoeper M, et al. Treatment of patients with mildly symptomatic pulmonary arterial hypertension with bosentan (EARLY study): a double-blind, randomised controlled trial. Lancet. 2008;371:2093–100.

    Article  CAS  PubMed  Google Scholar 

  19. Humbert M, Barst RJ, Robbins IM, et al. Combination of bosentan with epoprostenol in pulmonary arterial hypertension: BREATHE-2. Eur Respir J. 2004;24:353–9.

    Article  CAS  PubMed  Google Scholar 

  20. Rubin LJ, Badesch DB, Barst RJ, et al. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med. 2002;346:896–903.

    Article  CAS  PubMed  Google Scholar 

  21. Galié N, Olschewski H, Oudiz RJ, et al. Ambrisentan for the treatment of pulmonary arterial hypertension. Results of the ambrisentan in pulmonary arterial hypertension, randomized, double-blind, placebo-controlled, multicenter, efficacy (ARIES) study 1 and 2. Circulation. 2008;117:3010–9.

    Article  PubMed  CAS  Google Scholar 

  22. Pulido T, Adzerikho I, Channick RN, et al. Macitentan and morbidity and mortality in pulmonary arterial hypertension. N Engl J Med. 2013;369:809–18.

    Article  CAS  PubMed  Google Scholar 

  23. Galie N, Ghofrani HA, Torbicki A, et al. Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med. 2005;353:2148–57.

    Article  CAS  PubMed  Google Scholar 

  24. Iversen K, Jensen AS, Jensen TV, et al. Combination therapy with bosentan and sildenafil in Eisenmenger syndrome: a randomized, placebo-controlled, double-blinded trial. Eur Heart J. 2010;31:1124–31.

    Article  CAS  PubMed  Google Scholar 

  25. Sastry BKS, Narasimhan C, Reddy NK, et al. Clinical efficacy of sildenafil in primary pulmonary hypertension: a randomized, placebo-controlled, double-blind, crossover study. J Am Coll Cardiol. 2004;43:1149–53.

    Article  CAS  PubMed  Google Scholar 

  26. Singh T, Rohit M, Grover A, et al. A randomized, placebo-controlled, double-blind, crossover study to evaluate the efficacy of oral sildenafil therapy in severe pulmonary artery hypertension. Am Heart J. 2006;151:851.e1–5.

    Article  Google Scholar 

  27. Galiè N, Brundage BH, Ghofrani HA, et al. Tadalafil therapy for pulmonary arterial hypertension. Circulation. 2009;119(22):2894–903.

    Article  PubMed  CAS  Google Scholar 

  28. Jing ZC, Yu ZX, Shen JY, et al. Vardenafil in pulmonary arterial hypertension: a randomized, double-blind, placebo-controlled study. Am J Respir Crit Care Med. 2011;183:1723–9.

    Article  CAS  PubMed  Google Scholar 

  29. Ghofrani HA, Galiè N, Grimminger F, et al. Riociguat for the treatment of pulmonary arterial hypertension. N Engl J Med. 2013;369:330–40.

    Article  CAS  PubMed  Google Scholar 

  30. Fattouch K, Sbraga F, Bianco G, et al. Inhaled prostacyclin, nitricoxide, and nitroprusside in pulmonary hypertension after mitral valve replacement. J Card Surg. 2005;20:171–6.

    Article  PubMed  Google Scholar 

  31. Weill D, Benden C, Corris PA, et al. A consensus document for the selection of lung transplant candidates: 2014—an update from the Pulmonary Transplantation Council of the International Society for Heart and Lung Transplantation. J Heart Lung Transplant. 2015;34:1–15.

    Article  PubMed  Google Scholar 

  32. Galie N, Barbera JA, Frost AE, et al. Initial use of ambrisentan plus tadalafil in pulmonary arterial hypertension. N Engl J Med. 2015;373:834–44.

    Article  CAS  PubMed  Google Scholar 

  33. Butler J, Chomsky DB, Wilson JR. Pulmonary hypertension and exercise intolerance in patients with heart failure. J Am Coll Cardiol. 1999;34:1802–6.

    Article  CAS  PubMed  Google Scholar 

  34. Ghio S, Gavazzi A, Campana C, et al. Independent and additive prognostic value of right ventricular systolic function and pulmonary artery pressure in patients with chronic heart failure. J Am Coll Cardiol. 2001;37:183–8.

    Article  CAS  PubMed  Google Scholar 

  35. Lam CS, Roger VL, Rodeheffer RJ, et al. Pulmonary hypertension in heart failure with preserved ejection fraction: a community-based study. J Am Coll Cardiol. 2009;53:1119–26.

    Article  PubMed  PubMed Central  Google Scholar 

  36. Califf RM, Adams KF, McKenna WJ, et al. A randomized controlled trial of epoprostenol therapy for severe congestive heart failure: the Flolan international randomized survival trial (FIRST). Am Heart J. 1997;134:44–54.

    Article  CAS  PubMed  Google Scholar 

  37. Teerlink JR. Recent heart failure trials of neurohormonal modulation (OVERTURE and ENABLE): approaching the asymptote of efficacy? J Card Fail. 2002;8:124–7.

    Article  PubMed  Google Scholar 

  38. Guazzi M, Vicenzi M, Arena R, Guazi MD. Pulmonary hypertension in heart failure with preserved ejection fraction: a target of phosphodiesterase-5 inhibition in a 1 year study. Circulation. 2011;124:164–74.

    Article  CAS  PubMed  Google Scholar 

  39. Lewis GD, Shah R, Shahzad K, et al. Sildenafil improves exercise capacity and quality of life in patients with systolic heart failure and secondary pulmonary hypertension. Circulation. 2007;116:1555–62.

    Article  CAS  PubMed  Google Scholar 

  40. Hoendermis ES, Liu LC, Hummel YM, et al. Effects of sildenafil on invasive haemodynamics and exercise capacity in heart failure patients with preserved ejection fraction and pulmonary hypertension: a randomized controlled trial. Eur Heart J. 2015;36:2565–73.

    Article  CAS  PubMed  Google Scholar 

  41. Redfield MM, Chen HH, Borlaug BA, et al. Effect of phosphodiesterase-5 inhibition on exercise capacity and clinical status in heart failure with preserved ejection fraction: a randomized clinical trial. JAMA. 2013;309:1268–77.

    Article  CAS  PubMed  Google Scholar 

  42. Bermejo J, Yotti R, Garcia-Orta R, et al. Sildenafil for improving outcomes in patients with corrected valvular heart disease and persistent pulmonary hypertension: a multicenter, double-blind, randomized clinical trial. Eur Heart J. 2018;39:1255–64.

    Article  CAS  PubMed  Google Scholar 

  43. Bonderman D, Ghio S, Felix SB, et al. Riociguat for patients with pulmonary hypertension caused by systolic left ventricular dysfunction: a phase IIb double-blind, randomized, placebo-controlled, dose ranging hemodynamic study. Circulation. 2013;128:502–11.

    Article  CAS  PubMed  Google Scholar 

  44. Zhang H, Zhang J, Chen M, et al. Pulmonary artery denervation significantly increases 6-min walk distance for patients with combined pre- and post-capillary pulmonary hypertension associated with left heart failure: the PADN-5 study. JACC Cardiovasc Interv. 2019;12(3):274–84.

    Article  PubMed  Google Scholar 

  45. Chaouat A, Bugnet AS, Kadaoui N, et al. Severe pulmonary hypertension and chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2005;172:189–94.

    Article  PubMed  Google Scholar 

  46. Thabut G, Dauriat G, Stern JB, et al. Pulmonary hemodynamics in advanced COPD candidates for lung volume reduction surgery or lung transplantation. Chest. 2005;127:1531–6.

    Article  PubMed  Google Scholar 

  47. Hoeper MM, Schwarze M, Ehlerding S, et al. Long-term treatment of primary pulmonary hypertension with aerosolized iloprost, a prostacyclin analogue. N Engl J Med. 2000;342:1866–70.

    Article  CAS  PubMed  Google Scholar 

  48. Lang IM, Pesavento R, Bonderman D, et al. Risk factors and basic mechanisms of chronic thromboembolic pulmonary hypertension: a current understanding. Eur Respir J. 2013;41:462–8.

    Article  PubMed  Google Scholar 

  49. Tunariu N, Gibbs SJR, Win Z, et al. Ventilation-perfusion scintigraphy is more sensitive than multidetector CTPA in detecting chronic thromboembolic pulmonary disease as a treatable cause of pulmonary hypertension. J Nucl Med. 2007;48:680–4.

    Article  PubMed  Google Scholar 

  50. Mahmud E, Behnamgar O, Ang L, et al. Balloon pulmonary angioplasty for chronic thromboembolic pulmonary hypertension. Interv Cardiol Clin. 2018;1:103–17.

    Google Scholar 

Download references

Acknowledgements

The authors would like to thank Jonathan Clark, MD for his work on the previous edition of this chapter.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Gregory D. Lewis .

Editor information

Editors and Affiliations

Rights and permissions

Reprints and permissions

Copyright information

© 2021 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

van Beuningen, A.M., Lewis, G.D. (2021). Pulmonary Hypertension. In: Gaggin, H.K., Januzzi Jr., J.L. (eds) MGH Cardiology Board Review. Springer, Cham. https://doi.org/10.1007/978-3-030-45792-1_12

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-45792-1_12

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-45791-4

  • Online ISBN: 978-3-030-45792-1

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics